SBIR, Research and Development
Share |

SBIR, Research and Development

The successful development and innovation of medical technologies is contignent upon a favorable economic and regulatory environment. Programs such as the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (SBTT) remain essential to ensuring that start-up medical technology companies can access capital to develop the next generation of medical interventions. Tax credits, such as the Research and Development credit, must be preserved so smaller companies have the appropriate incentives to innovate. MDMA is active in ensuring that both the SBIR and R&D tax credits are structured and preserved in a manner that will aide in the furtherance of innovative medical technology development.